Menu
GWAS Study

Multi-Trait Genome-Wide Association Study of Atherosclerosis Detects Novel Pleiotropic Loci.

Bellomo TR, Bone WP, Chen BY et al.

35186008 PubMed ID
GWAS Study Type
1529087 Participants
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

BT
Bellomo TR
BW
Bone WP
CB
Chen BY
GK
Gawronski KAB
ZD
Zhang D
PJ
Park J
LM
Levin M
TN
Tsao N
KD
Klarin D
LJ
Lynch J
AT
Assimes TL
GJ
Gaziano JM
WP
Wilson PW
CK
Cho K
VM
Vujkovic M
OC
O'Donnell CJ
CK
Chang KM
TP
Tsao PS
RD
Rader DJ
RM
Ritchie MD
DS
Damrauer SM
VB
Voight BF
Chapter II

Abstract

Summary of the research findings

Although affecting different arterial territories, the related atherosclerotic vascular diseases coronary artery disease (CAD) and peripheral artery disease (PAD) share similar risk factors and have shared pathobiology. To identify novel pleiotropic loci associated with atherosclerosis, we performed a joint analysis of their shared genetic architecture, along with that of common risk factors. Using summary statistics from genome-wide association studies of nine known atherosclerotic (CAD, PAD) and atherosclerosis risk factors (body mass index, smoking initiation, type 2 diabetes, low density lipoprotein, high density lipoprotein, total cholesterol, and triglycerides), we perform 15 separate multi-trait genetic association scans which resulted in 25 novel pleiotropic loci not yet reported as genome-wide significant for their respective traits. Colocalization with single-tissue eQTLs identified candidate causal genes at 14 of the detected signals. Notably, the signal between PAD and LDL-C at the PCSK6 locus affects PCSK6 splicing in human liver tissue and induced pluripotent derived hepatocyte-like cells. These results show that joint analysis of related atherosclerotic disease traits and their risk factors allowed identification of unified biology that may offer the opportunity for therapeutic manipulation. The signal at PCSK6 represent possible shared causal biology where existing inhibitors may be able to be leveraged for novel therapies.

24,009 European ancestry peripherial artery disease cases, 122,733 European ancestry coronary artery disease cases, 575,511 European ancestry controls, 806, 834 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

1529087
Total Participants
GWAS
Study Type
No
Replicated
European
Ancestry
U.S., U.K., Sweden, Pakistan, Japan
Recruitment Country
Chapter IV

Analysis

Comprehensive review of health and genetic findings

Important Disclaimer: This review has been performed semi-automatically and is provided for informational purposes only. While we strive for accuracy, this analysis may contain errors, omissions, or misinterpretations of the original research. DNA Genics disclaims all liability for any inaccuracies, errors, or consequences arising from the use of this information. Users should independently verify all information and consult original research publications before making any decisions based on this content. This analysis is not intended as a substitute for professional scientific review or medical advice.

Analysis In Progress

Our analysis of this publication is currently being prepared. Please check back soon for comprehensive insights into the health and genetic findings discussed in this research.